Hyperoxia
PreclinicalBiologic
Hyperoxia is one of 31 biologic programs targeting Interstitial Lung Disease. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
36 competitors in Interstitial Lung Disease
#DrugCompanyPhaseTrials
1Rituxan
RocheApproved
Tracleer
Johnson & JohnsonApproved
Actemra
RocheApproved
Trexall
Jazz PharmaceuticalsApproved
Medrol
PfizerApproved
Esbriet
LLegacy Health System
Approved
Cytoxan
BBaxter Healthcare Corporation
Approved
Imuran
LLegacy Health System
Approved
Ofev
Boehringer IngelheimPhase 3
Avinza
HHikma Pharmaceuticals LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ischemia1 trial
Oxygen Therapy for Retinal Ischemia
Withdrawn·—·Phase 4·NCT03730779
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hyperoxia. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of British Columbia